CCDC82 Inhibitors
CCDC82 inhibitors are a diverse group of compounds that indirectly affect the functional activity of CCDC82 via various cellular and molecular mechanisms. For example, WZB117 operates by inhibiting GLUT1, leading to reduced glucose uptake which could indirectly inhibit CCDC82 if it is involved in glucose-dependent metabolic processes. Similarly, MLN4924's inhibition of the NEDD8-activating enzyme impacts protein ubiquitination pathways, which could decrease CCDC82's stability or modulate its activity if CCDC82 is regulated by ubiquitination. Ibrutinib, acting as a BTK inhibitor, potentially reduces CCDC82 activity by impairing B-cell receptor signaling pathways that CCDC82 might be part of. Moreover, Alisertib's inhibition of Aurora kinase A, by disrupting cell cycle progression, could lead to decreased CCDC82 activity if CCDC82 has regulatory roles in cell division.
The action of Bafilomycin A1 as a V-ATPase inhibitor affects lysosomal acidification, which could decrease CCDC82 activity if it is associated with lysosomal function. Venetoclax, through its Bcl-2 inhibitory action, could disrupt the survival signals that maintain CCDC82 activity and stability, leading to an indirect decrease in its functional role, especially if CCDC82 has anti-apoptotic functions or interacts with Bcl-2 family proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
A glucose transporter 1 (GLUT1) inhibitor that hinders glucose uptake. If CCDC82 is involved in metabolic pathways dependent on glucose, the inhibition of GLUT1 can decrease the energy supply necessary for CCDC82's function, leading to its functional inhibition. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
An inhibitor of NEDD8-activating enzyme, essential for cullin-RING ligase function, which plays a role in protein ubiquitination. If CCDC82 stability or activity is regulated by ubiquitination, inhibition of this pathway can prevent its proper function. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
A Bruton's tyrosine kinase (BTK) inhibitor that impairs B-cell receptor signaling. If CCDC82 is involved in B-cell receptor pathway processes, the inhibition of BTK can lead to a decrease in CCDC82 functional activity. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
An Aurora kinase A inhibitor which disrupts cell cycle progression. If CCDC82 has a role in cell cycle regulation through Aurora kinase A, alisertib can inhibit this pathway, leading to decreased CCDC82 activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A V-ATPase inhibitor that disrupts lysosomal acidification. If CCDC82 is localized to lysosomes or is involved in lysosomal-dependent processes, inhibition of lysosomal function can decrease CCDC82 activity. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
A Bcl-2 inhibitor that promotes apoptosis. If CCDC82 has anti-apoptotic roles or relies on Bcl-2 for its stability or function, ABT-199 can indirectly inhibit CCDC82 by disrupting its survival signals. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that leads to cell cycle arrest. If CCDC82 activity is associated with the cell cycle progression facilitated by CDK4/6, palbociclib can lead to a decrease in CCDC82 activity. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
An ERK1/2 inhibitor that impairs the MAPK/ERK signaling pathway. If CCDC82 is a downstream effector of this pathway, inhibition of ERK1/2 can lead to decreased CCDC82 activity. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
An Src family kinase inhibitor that impedes multiple signaling pathways. If CCDC82's function is modulated through Src kinase-mediated pathways, inhibition by saracatinib can lead to decreased CCDC82 activity. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
A MEK inhibitor that disrupts the MAPK/ERK signaling pathway. If CCDC82 functions downstream of MEK, cobimetinib can inhibit the pathway, leading to decreased CCDC82 activity. | ||||||